0QSS Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.92 |
| 52 Week High | €11.02 |
| 52 Week Low | €2.82 |
| Beta | 1.79 |
| 1 Month Change | 1.90% |
| 3 Month Change | -30.70% |
| 1 Year Change | -65.18% |
| 3 Year Change | -95.20% |
| 5 Year Change | -95.89% |
| Change since IPO | -98.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QSS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.3% |
| 1Y | -65.2% | -29.5% | 0.6% |
Return vs Industry: 0QSS underperformed the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0QSS underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0QSS volatility | |
|---|---|
| 0QSS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QSS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0QSS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| 0QSS fundamental statistics | |
|---|---|
| Market cap | €17.74m |
| Earnings (TTM) | -€23.49m |
| Revenue (TTM) | €1.33m |
13.4x
P/S Ratio-0.8x
P/E RatioIs 0QSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QSS income statement (TTM) | |
|---|---|
| Revenue | €1.33m |
| Cost of Revenue | €0 |
| Gross Profit | €1.33m |
| Other Expenses | €24.81m |
| Earnings | -€23.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,771.34% |
| Debt/Equity Ratio | 39.8% |
How did 0QSS perform over the long term?
See historical performance and comparison